Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network

Mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) cause autosomal dominant forms of Alzheimer disease (ADAD). More than 280 pathogenic mutations have been reported in APP, PSEN1, and PSEN2. However, understanding of the basic biological mechanisms that drive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's research & therapy 2018-07, Vol.10 (1), p.69-11, Article 69
Hauptverfasser: Karch, Celeste M, Hernández, Damián, Wang, Jen-Chyong, Marsh, Jacob, Hewitt, Alex W, Hsu, Simon, Norton, Joanne, Levitch, Denise, Donahue, Tamara, Sigurdson, Wendy, Ghetti, Bernardino, Farlow, Martin, Chhatwal, Jasmeer, Berman, Sarah, Cruchaga, Carlos, Morris, John C, Bateman, Randall J, Pébay, Alice, Goate, Alison M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) cause autosomal dominant forms of Alzheimer disease (ADAD). More than 280 pathogenic mutations have been reported in APP, PSEN1, and PSEN2. However, understanding of the basic biological mechanisms that drive the disease are limited. The Dominantly Inherited Alzheimer Network (DIAN) is an international observational study of APP, PSEN1, and PSEN2 mutation carriers with the goal of determining the sequence of changes in presymptomatic mutation carriers who are destined to develop Alzheimer disease. We generated a library of 98 dermal fibroblast lines from 42 ADAD families enrolled in DIAN. We have reprogrammed a subset of the DIAN fibroblast lines into patient-specific induced pluripotent stem cell (iPSC) lines. These cells were thoroughly characterized for pluripotency markers. This library represents a comprehensive resource that can be used for disease modeling and the development of novel therapeutics.
ISSN:1758-9193
1758-9193
DOI:10.1186/s13195-018-0400-0